# A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Study · id `cardio:ct-nct03018665` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03018665](<https://clinicaltrials.gov/study/NCT03018665>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03018665

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03018665. Randomized; no masking; primary purpose treatment. Start 2017-02 (registry gives no type); primary completion 2021-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03018665, source copy `cardio:ctgov-nct03018665-2017-01-12`, retrieved 2026-10-26)
- Start date: 2017-02 (registry gives no type) (ClinicalTrials.gov record NCT03018665, source copy `cardio:ctgov-nct03018665-2017-01-12`, retrieved 2026-10-26)
- Primary completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03018665, source copy `cardio:ctgov-nct03018665-2017-01-12`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: China (ClinicalTrials.gov record NCT03018665, source copy `cardio:ctgov-nct03018665-2017-01-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03018665-2017-01-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Exenatide
- Intervention (Drug): BIAsp30
- Intervention (Drug): Metformin
- Lead sponsor: The First Hospital of Jilin University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The First Hospital of Jilin University (`cardio:org-the-first-hospital-of-jilin-university`)

## Provenance

Content hash: bee22796dfa46ccfe426a7bca655c537190801af7d8539ee76324249cab48275
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
